Which are the best prescription-drug combinations for the worst cases of CFS?
CFS patients who need a combination of corticoids and non-steroidal anti-inflammatory drugs are likely to have severe symptoms.
According to a new report, a mix of cortisone and a non-specific anti-inflammatories is likely to be the best choice.
The report comes from a study published in the journal Clinical Practice: Research.
The authors of the study said the combination of non-surgical corticoid and corticosterone could be “a viable option” for those suffering from the CFS and COPD conditions.
The study, which is funded by the National Institutes of Health, was conducted on a sample of patients with COPD and CFS.
The researchers examined data from the National Health and Nutrition Examination Survey (NHANES) of 2010.
The data showed that approximately 14% of the sample were taking a combination.
Those who were taking either cortisol or corticotron used to treat COPD, and those taking both were also in the study.
The most common non-Steroidal Anti-inflammatory Drug (NSAID) used in the group was Advil.
The number of patients taking the NSAID, however, was less than half that of those who took the cortisole.
The group also used the corticostin combination more than the non-NSAID group.
“The most common use of NSAIDs in COPD was for cough, sneezing, or chest pain,” the authors said in the report.
They said that the NSAIDs were also used to reduce the symptoms of cough and other symptoms associated with COPA.
“While there are many non-selective NSAIDs, they are commonly used for cough and bronchitis, asthma, and chronic obstructive pulmonary disease,” they said.
A combination of NSAID and cortisomodulators for COPD patients has also been reported in other studies.
“Our study provides some support for the potential role of nonsteroidal NSAIDs for the treatment of COPD,” said lead author Jodi Kupfer, MD, PhD, associate professor of psychiatry at the University of California, San Francisco.
“But, there are a number of limitations.”
The authors did not examine the effects of the NSAIDS on COPD symptoms.
The investigators found that there was “no significant difference” between the NSAid combination and the nonsteroid one in the patients with CFS who were not taking cortisoles.
The patients who were on non-antihistamines or non-medicated non-inflammatory therapy for COPDs were also less likely to use NSAIDs.
The team also noted that there is no evidence that NSAIDs or cortisoids are helpful for those who have COPD.
The only possible benefit of nonspecific NSAIDs is for treatment of COVID-19-related symptoms, which include chest pain, fever, muscle pain, and muscle spasms.
“We need to continue to assess the benefits and risks of NSAIDS for patients with COVID disease, particularly for patients who are at high risk for COVID and/or are currently taking a nonsteriotic combination,” the researchers said.